Prostate-specific antigen response to withdrawal of megestrol acetate in a patient with hormone-refractory prostate cancer

被引：0

作者：

Wehbe, TW ^{[1
]}

Stein, BS ^{[1
]}

Akerley, WL ^{[1
]}

机构：

[1] RHODE ISL HOSP,DEPT UROL,PROVIDENCE,RI 02902

来源：

MAYO CLINIC PROCEEDINGS | 1997年 / 72卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Clinically significant responses after withdrawal of flutamide in patients with hormone-refractory prostate cancer (HRPC) are well documented. Failure to recognize this syndrome of response results in potential morbidity due to salvage therapy, confusion in interpretation of disease state, and introduction of a possible source of error in clinical trials, In this case report, we describe a patient with HRPC whose prostate-specific antigen levels decreased substantially in response to withdrawal of megestrol acetate. Such a response should be considered when megestrol acetate is used in the treatment of HRPC.

引用

收藏

页码：932 / 934

页数：3

相关论文

共 50 条

[41] COMPLETE REMISSION OF HORMONE-REFRACTORY ADENOCARCINOMA OF THE PROSTATE IN RESPONSE TO WITHDRAWAL OF DIETHYLSTILBESTROL [J].

BISSADA, NK ;

KACZMAREK, AT .

JOURNAL OF UROLOGY, 1995, 153 (06) :1944-1945

[42] Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer [J].

Egawa, S ;

Okusa, H ;

Matsumoto, K ;

Suyama, K ;

Baba, S .

PROSTATE CANCER AND PROSTATIC DISEASES, 2003, 6 (03) :245-249

[43] Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer [J].

S Egawa ;

H Okusa ;

K Matsumoto ;

K Suyama ;

S Baba .

Prostate Cancer and Prostatic Diseases, 2003, 6 :245-249

[44] External beam radiotherapy for clinically localized hormone-refractory prostate cancer: Clinical significance of nadir prostate-specific antigen within 12 months [J].

Ogawa, K. ;

Nakamura, K. ;

Sasaki, T. ;

Onishi, H. ;

Koizumi, M. ;

Shioyama, Y. ;

Araya, M. ;

Okamoto, A. ;

Mitsumori, M. ;

Teshima, T. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01) :S55-S56

[45] Marked leukocytosis in response to estramustine phosphate in a hormone-refractory prostate cancer patient [J].

Morita, Tatsuo .

INTERNATIONAL MEDICAL CASE REPORTS JOURNAL, 2010, 3 :39-41

[46] Hormonal sensitivity following endocrine withdrawal in hormone-refractory prostate cancer [J].

Nishiyama, T ;

Terunuma, M .

UROLOGIA INTERNATIONALIS, 2000, 65 (01) :28-31

[47] Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: Relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study [J].

Berthold, Dominik R. ;

Pond, Gregory R. ;

Roessner, Martin ;

de Wit, Ronald ;

Eisenberger, Mario ;

Tannock, Ian F. .

CLINICAL CANCER RESEARCH, 2008, 14 (09) :2763-2767

[48] Prostate-specific antigen and prostate cancer [J].

Rosalki, SB ;

Rutherford, FJ .

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2000, 54 (09) :611-613

[49] The use of prostate-specific antigen as a surrogate end point in the treatment of patients with hormone refractory prostate cancer [J].

Smith, DC ;

Pienta, KJ .

UROLOGIC CLINICS OF NORTH AMERICA, 1997, 24 (02) :433-&

[50] Chemotherapy of the hormone-refractory prostate cancer [J].

Heine, K ;

Wolff, JM .

AKTUELLE UROLOGIE, 2004, 35 (03) :209-214

← 1 2 3 4 5 →